March 2012
Volume 53, Issue 14
ARVO Annual Meeting Abstract  |   March 2012
Antiphospholipid syndrome in Mexican population
Author Affiliations & Notes
  • Claudia Recillas-Gispert
    Ophthalmology, INCMNSZ, Mexico City, Mexico
  • Juan Carlos Martinez
    Ophthalmology, INCMNSZ, Mexico City, Mexico
  • Footnotes
    Commercial Relationships  Claudia Recillas-Gispert, None; Juan Carlos Martinez, None
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science March 2012, Vol.53, 6248. doi:
  • Views
  • Share
  • Tools
    • Alerts
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Claudia Recillas-Gispert, Juan Carlos Martinez; Antiphospholipid syndrome in Mexican population. Invest. Ophthalmol. Vis. Sci. 2012;53(14):6248.

      Download citation file:

      © ARVO (1962-2015); The Authors (2016-present)

  • Supplements

Purpose: : To determine the prevalence of Antiphospholipid syndrome in the Mexican population over 10 years, and the frequency of ocular manifestations, and which of those cases were the first manifestation of the disease.

Methods: : Retrospective, observational, transversal and descriptive study reviewing the medical files and records from all patients with Antiphospholipid syndrome’s diagnostic with descriptive statistical analysis for age, gender, type of antiphospholipid syndrome (primary or secondary), ocular manifestations and visual acuity at our hospital in a period of 10 years.

Results: : We include 332 patients with diagnostic of Antiphospholipid syndrome. Mean age at the moment of the diagnostic was 29.54 years. 278 were women (83.73%). 141 patients (42.85%) were diagnosed with Primary Antiphospholipid syndrome (PAPS), which 9 patients (6.38%) were ocular PAPS; 191 patients (57.17%) with Secondary Antiphospholipid syndrome (SAPS), 14 patients (7.33%) presented one ocular thrombotic episode without other systemic episode. Patients with ocular vasso-oclusive manifestations were 15 with central vein vascular oclussion (CRVO):8, central arteriy vascular oclusion (CAVO): 6, branch retinal artery oclusion: 1, optic neuritis:12, retinal vasculitis:7 amaurosis fugax:3. Other ocular autoimmune manifestations: epiescleritis: 2, escleritis:2, papiledema:1, internuclear ophthalmoplegic: 1, uveitis:1.Visual prognosis in patients with ocular manifestations presented a wide range associated to the type of alteration. Patients with legal blindness in PAPS were 3: 2 related to CRAO and the other one with optical neuritis, while patients with SAPS were 6: 2 with CRVO, 2 retinal vasculitis, 1 with CRAO and 1 with optic neuritis.

Conclusions: : Ocular manifestations in antiphospholipid syndrome have a low prevalence with a tendency to be more affected in the SAPS, may be because of comorbility with other diseases. However, they have great impact on the visual prognosis, so it is important to do timely assessment on suspected APS patients.

Keywords: vascular occlusion/vascular occlusive disease • autoimmune disease • clinical (human) or epidemiologic studies: prevalence/incidence 

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.